Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate

Annals of Oncology

Volumn 13, Issue 12, 2002, Pages 1915-1918

  Chiusolo, P ^a   Reddiconto, G ^a   Casorelli, I ^a   Laurenti, L ^a   Sora F ^a   Mele, L ^a   Annino, L ^b   Leone, G ^a   Sica, S ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Methotrexate; MTHFR; Polymorphism

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYCLOPHOSPHAMIDE; CYTOSINE; DAUNORUBICIN; FLUOROURACIL; MERCAPTOPURINE; METHOTREXATE; METHYLENETETRAHYDROFOLIC ACID; PREDNISONE; THYMINE; VINCRISTINE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CATALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; FOLATE METABOLISM; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HEMATOLOGIC DISEASE; HOMOZYGOSITY; HUMAN; INCIDENCE; ITALY; LIVER TOXICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC SCREENING; HOMOZYGOTE; HUMANS; LEUKEMIA; MALE; MAXIMUM TOLERATED DOSE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 0036928840     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf322     Document Type: Article

References (14)

1. De Stefano V, Chiusolo P, Paciaroni K et al. Prevalence of the 677C to T mutation in the methylenetetrahydrofolate reductase gene in Italian patients with venous thrombotic disease. Thromb Haemost 1998; 79: 686-687.
2. Ueland PM, Hustad S, Schneede J et al. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001; 22: 195-201.
3. Payne DA, Chamoun AJ, Seifert SL, Stouffer GA. MTHFR C677T mutation. A predictor of early-onset coronary artery disease risk. Thromb Res 2001; 103: 275-279.
4. Shields DC, Kirke PN, Mills JL et al. The 'thermolabile' variant of methylenetetrahydrofolate reductase and neural tube defects: an evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother. Am J Hum Genet 1999; 64: 1045-1055.
5. Ulrich CM, Yasui Y, Storb R et al. Pharmacogenomics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001; 98: 231-234.
6. Mandelli F, Annino L, Vegna ML et al. GIMEMA ALL 0288: a multicentric study on adult acute lymphoblastic leukemia. Preliminary results. Leukemia 1992; 6: 182-185.
7. Avvisati G, Lo Coco F, Diverio D et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyclocytic leukemia: a Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390-1398.
8. Schubert MM, Williams BE, Lloid ME et al. Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer 1992; 69: 2469-2477.
9. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
10. Balis FM, Holcenberg JS, Poplack DG et al. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: ajoint Children's Cancer Group and Pediatric Oncology Branch study. Blood 1998; 92: 3569-3577.
11. Toffoli G, Veronesi A, Boiocchi M, Crivellari D. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). Ann Oncol 2000; 11: 373-375.
12. Evans WE, Han YY, Bomgaars L et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001; 19: 2293-2301.
13. Sekine I, Saijo N. Polymorphism of metabolizing enzymes and transport proteins involved in the clearance of anticancer agents. Ann Oncol 2001; 12: 1515-1525.
14. Matsuo K, Suzuki R, Morishima Y, Hamajima N. Attribution of posttransplantation toxicity to methotrexate regarding genotype of methylenetetrahydrofolate reductase gene (MTHFR) polymorphism needs further clarification (letter). Blood 2001; 98: 2283.